Tissue Biopsy | Liquid Biopsy Test | Liquid Biopsy Testing

When Tissue Biopsy is not feasible, try FoundationOne®Liquid – Liquid Biopsy Test. It opens up the opportunity of comprehensive genomic profiling for solid tumour patients.

Our FDA-approved liquid biopsy comprehensive genomic profiling service offers a minimally-invasive option, alternative or complementary to FoundationOne CDx, for all patients with solid tumours at optimal times beneficial to their treatment journey.

FoundationOne Liquid CDx reports 300 genes and is able to detect both novel and known variants, including four classes of genomic alterations (base substitutions, insertions or deletions, copy number alterations and gene rearrangements), genomic signatures and Tumour Fraction, to provide prognostic, diagnostic and predictive insights that inform research or treatment decisions for individual patients across all solid tumours.

Leave a Reply

Your email address will not be published. Required fields are marked *